DSpace Repository

Antiepileptic drug use for treatment of epilepsy and dyslipidemia: Systematic review

Show simple item record

dc.contributor.author Vyas, Manav V.
dc.contributor.author Davidson, Benjamin Andrew
dc.contributor.author Escalaya, Leonardo
dc.contributor.author Costella, John
dc.contributor.author Saposnik, Gustavo
dc.contributor.author Burneo, Jorge G.
dc.date.accessioned 2019-02-06T14:52:19Z
dc.date.available 2019-02-06T14:52:19Z
dc.date.issued 2015
dc.identifier.uri https://hdl.handle.net/20.500.12866/5308
dc.description.abstract OBJECTIVE: To characterize the association between commonly used anti-epileptic drugs (AEDs) and plasma lipid levels in patients with epilepsy. METHODS: We sought observational studies that reported association between commonly used AEDs and plasma lipid levels in patients. The primary outcome was low-density lipoprotein (LDL) cholesterol. High-density lipoprotein (HDL), total cholesterol and triglyceride were secondary outcomes. The control group included healthy controls, pre-treatment patients or patients treated with other AEDs. We conducted a systematic search of major bibliographic databases and review of reference lists of primary articles and reviews. Primary comparisons of interest were: AED monotherapy vs. no AED use, monotherapy with one AED vs. other AED, and AED polytherapy vs. no AED use. RESULTS: 31 studies in 4126 people were identified. Carbamazepine, phenytoin and valproic acid were the most commonly studied drugs and were also implicated in causing considerable changes in plasma lipid levels in treated patients. There was an increase in LDL and total cholesterol levels with use of these three drugs; however, carbamazepine and phenytoin were also associated with higher levels of HDL. We could not identify one particular AED which was worse than the other in head-to-head comparison. We were unable to identify a particular polytherapy regimen that was worse than others. CONCLUSION: We found evidence to suggest that some AEDs may negatively alter lipids levels in patients with epilepsy. Both treating physicians and people with epilepsy need to be vigilant in managing their vascular risk factors to avoid vascular disease. en_US
dc.language.iso eng
dc.publisher Elsevier
dc.relation.ispartof urn:issn:1872-6844
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Humans en_US
dc.subject Animals en_US
dc.subject Dyslipidemia en_US
dc.subject Epilepsy en_US
dc.subject Systematic review en_US
dc.subject Anticonvulsants/therapeutic use en_US
dc.subject Antiepileptic drugs en_US
dc.subject Databases, Bibliographic/statistics & numerical data en_US
dc.subject Dyslipidemias/drug therapy en_US
dc.subject Epilepsy/drug therapy en_US
dc.subject Lipids/blood en_US
dc.subject Vascular en_US
dc.title Antiepileptic drug use for treatment of epilepsy and dyslipidemia: Systematic review en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1016/j.eplepsyres.2015.03.002
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.00 es_PE
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.25


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


Browse

My Account

Statistics